Targeting Rho GTPase signaling for cancer therapy

Future Oncology

Volumn 8, Issue 2, 2012, Pages 165-177

  Mardilovich, Katerina ^a   Olson, Michael F ^a   Baugh, Mark ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

cancer therapy; chemical inhibitor; LIMK; MRCK; PAK; Rho GTPase; ROCK

Indexed keywords

4 (1 AMINOETHYL) N (1H PYRROLO[2,3 B]PYRIDIN 4 YL)CYCLOHEXANECARBOXAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ANTINEOPLASTIC AGENT; AZD 3409; CHELERYTHRINE; EHT 1864; EXOENZYME C3; FASUDIL; GSK 269962A; GUANINE NUCLEOTIDE EXCHANGE FACTOR; H 1152P; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEAD COMPOUND 14A; LIM KINASE 1; MLS 000532223; MLS 000573151; PF 3758309; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SB 7720770B; SCAFFOLD PROTEIN; TRIAP ALPHA; TRIP ALPHA; UNCLASSIFIED DRUG; Y 30946; Y 32885;

ACTIN POLYMERIZATION; ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; EMBRYONIC STEM CELL; ESSENTIAL HYPERTENSION; GLAUCOMA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSKELETON; ENZYME ACTIVATION; ENZYME INHIBITORS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LIM KINASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; P21-ACTIVATED KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84857296427     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.143     Document Type: Review

References (104)

1. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 84, 57-80 (2002). (Pubitemid 34188194)
2. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 1796(2), 91-98 (2009).
3. Spiering D, Hodgson L. Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh. Migr. 5(2), 170-180 (2011).
4. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin Genet. Dev. 15(1), 62-68 (2005). (Pubitemid 40127633)
5. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene 286(2), 155-174 (2002). (Pubitemid 34273873)
6. Shimokawa H, Seto M, Katsumata N et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43(4), 1029-1039 (1999). (Pubitemid 29413201)
7. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J. Mol. Med. 85(6), 555-568 (2007). (Pubitemid 46870893)
8. Olson MF. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 20(2), 242-248 (2008).
9. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat. Rev. Cancer 2(2), 133-142 (2002).
10. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 23(9), 1415-1423 (2011).
11. Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac signaling in tumorigenesis. Cell Cycle 10(10), 1571-1581 (2011).
12. Samuel MS, Olson MF. Dying alone: a tale of Rho. Cell Stem Cell 7(2), 135-136 (2010).
13. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul. Pharmacol. 39(4-5), 187-199 (2002).
14. Ghosh K, Thodeti CK, Dudley AC et al. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl Acad. Sci. USA 105(32), 11305-11310 (2008).
15. Carbajal JM, Schaeffer RC Jr. RhoA inactivation enhances endothelial barrier function. Am. J. Physiol. 277(5 Pt 1), C955-C964 (1999).
16. Van Nieuw Amerongen GP, Koolwijk P, Versteilen A, Van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler. Thromb. Vasc. Biol. 23(2), 211-217 (2003). (Pubitemid 36231930)
17. Doublier S, Riganti C, Voena C et al. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol. Cancer Res. 6(10), 1607-1620 (2008).
18. Croft DR, Crighton D, Samuel MS et al. p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival. Cell Res. 21(4), 666-682 (2011).
19. Chen QY, Xu LQ, Jiao DM et al. Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs. Int. J. Mol. Med. 28(5), 769-776 (2011).
20. Itoh K, Yoshioka K, Akedo H et al. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5(2), 221-225 (1999). (Pubitemid 29068531)
21. Somlyo AV, Bradshaw D, Ramos S et al. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 269(3), 652-659 (2000). (Pubitemid 30440356)
22. Somlyo AV, Phelps C, Dipierro C et al. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J. 17(2), 223-234 (2003). (Pubitemid 36164392)
23. Nakashima M, Adachi S, Yasuda I et al. Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. Mol. Cancer 10, 79 (2011).
24. Street CA, Routhier AA, Spencer C et al. Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int. J. Oncol. 37(5), 1297-1305 (2010).
25. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6(2), 167-180 (2005). (Pubitemid 40215811)
26. Lazer G, Katzav S. Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? Cell Signal. 23(6), 969-979 (2011).
27. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 16, 1587-1609 (2002). (Pubitemid 34743321)
28. Blangy A, Vignal E, Schmidt S et al. TrioGEF1 controls Rac-and Cdc42-dependent cell structures through the direct activation of RhoG. J. Cell Sci. 113(4), 729-739 (2000). (Pubitemid 30133050)
29. Debant A, Serra-Pags C, Seipel K et al. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate Rac-specific and Rho-specific guanine nucleotide exchange factor domains. Proc. Natl Acad. Sci. USA. 93(11), 5466-5471 (1996).
30. Lane J, Martin TA, Mansel RE, Jiang WG. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int. Semin. Surg. Oncol. 5, 23 (2008).
31. Salhia B, Tran NL, Chan A et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am. J. Pathol. 173(6), 1828-1838 (2008).
32. Yoshizuka N, Moriuchi R, Mori T et al. An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J. Biol. Chem. 279(42), 43998-44004 (2004). (Pubitemid 39390708)
33. Schmidt S, Diriong S, Méry J, Fabbrizio E, Debant A. Identification of the first Rho-GEF inhibitor, TRIPa, which targets the RhoA-specific GEF domain of Trio. FEBS Lett. 523(1), 35-42 (2002). (Pubitemid 34786054)
34. Bouquier N, Vignal E, Charrasse S et al. A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem. Biol. 16(6), 657-666 (2009).
35. Baines IC, Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today 11(7-8), 334-341 (2006).
36. Blangy A, Bouquier N, Gasuthier-Rouvire C et al. Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. Biol. Cell. 98(9), 511-522 (2006). (Pubitemid 44383368)
37. Kourlas PJ, Strout MP, Becknell B et al. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc. Natl Acad. Sci. USA 97(5), 2145-2150 (2000). (Pubitemid 30134036)
38. Jaiswal M, Gremer L, Dvorsky R et al. Mechanistic insights into specif?icity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG). J. Biol. Chem. 286(20), 18202-18212 (2011).
39. Evelyn CR, Ferng T, Rojas RJ et al. High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay. J. Biomol. Screen. 14(2), 161-172 (2009).
40. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101(20), 7618-7623 (2004). (Pubitemid 38658078)
41. Yoshida T, Zhang Y, Rivera Rosado LA et al. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 9(6), 1657-1668 (2010).
42. Wang J, Rao Q, Wang M et al. Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth. Biochem. Biophys. Res. Commun. 386(4), 769-774 (2009).
43. Hernández E, De La Mota-Peynado A, Dharmawardhane S, Vlaar CP. Novel inhibitors of Rac1 in metastatic breast cancer. P. R. Health Sci. J. 29(4), 348-356 (2010).
44. Preudhomme C, Roumier C, Hildebrand MP et al. Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene 19(16), 2023-2032 (2000). (Pubitemid 30229415)
45. Aktories K. Bacterial protein toxins that modify host regulatory GTPases. Nat. Rev. Microbiol. 9(7), 487-498 (2011).
46. Sekine A, Fujiwara M, Narumiya S. Asparagine residue in the Rho gene product is the modification site for botulinum ADP-ribosyltransferase. J. Biol. Chem. 264(15), 8602-8605 (1989). (Pubitemid 19151574)
47. Fujihara H, Walker LA, Gong MC et al. Inhibition of RhoA translocation and calcium sensitization by in vivo ADP-ribosylation with the chimeric toxin DC3B. Mol, Biol. Cell 8(12), 2437-2447 (1997). (Pubitemid 27528212)
48. Genth H, Gerhard R, Maeda A et al. Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. J. Biol. Chem. 278(31), 28523-28527 (2003). (Pubitemid 36935755)
49. Winton MJ, Dubreuil CI, Lasko D, Leclerc N, McKerracher L. Characterization of new cell permeable C3-like proteins that inactivate Rho and stimulate neurite outgrowth on inhibitory substrates. J. Biol. Chem. 277(36), 32820-32829 (2002). (Pubitemid 34984792)
50. Sahai E, Olson MF. Purification of TAT-C3 exoenzyme. Methods Enzymol. 406, 128-140 (2006). (Pubitemid 43207437)
51. Lord-Fontaine S, Yang F, Diep Q et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J. Neurotrauma 25(11), 1309-1322 (2008).
52. Fehlings MG, Theodore N, Harrop J et al. A Phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 28(5), 787-796 (2011).
53. Désiré L, Bourdin J, Loiseau N et al. RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases A-beta production in vitro and in vivo. J. Biol. Chem. 280(45), 37516-37525 (2005). (Pubitemid 41642360)
54. Shutes A, Onesto C, Picard V et al. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem. 282(49), 35666-35678 (2007). (Pubitemid 350277149)
55. Rosenblatt AE, Garcia MI, Lyons L et al. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr. Relat. Cancer 18(2), 207-219 (2011).
56. Surviladze Z, Waller A, Wu Y et al. Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay. J. Biomol. Screen. 15(1), 10-20 (2010).
57. Deng J, Feng E, Ma S et al. Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases? J. Med. Chem. 54(13), 4508-4522 (2011).
58. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280, 34202-34209 (2005). (Pubitemid 41443145)
59. Appels NM, Bolijn MJ, Chan K et al. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br. J. Cancer 98(12), 1951-1958 (2008). (Pubitemid 351821567)
60. Qiao Y, Gao J, Qiu Y et al. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I. Eur. J. Med. Chem. 46(6), 2264-2273 (2011).
61. Wickman GR, Samuel MS, Lochhead PA, Olson MF. The Rho-regulated ROCK kinases in cancer. In: The Rho GTPases in Cancer. Van Golen K (Ed.). Springer, NY, USA, 163-192 (2010).
62. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene 29(17), 2591-2598 (2010).
63. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389(6654), 990-994 (1997). (Pubitemid 27485693)
64. Amano M, Chihara K, Nakamura N et al. The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity. J. Biol. Chem. 274(45), 32418-32424 (1999).
65. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(Pt 1), 95-105 (2000).
66. Katsumata N, Shimokawa H, Seto M et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation 96(12), 4357-4363 (1997). (Pubitemid 28007466)
67. Satoh S, Utsunomiya T, Tsurui K et al. Pharmacological profile of hydroxy fasudil as a selective Rho kinase inhibitor on ischemic brain damage. Life Sci. 69(12), 1441-1453 (2001). (Pubitemid 32758711)
68. Zhao J, Zhou D, Guo J et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol. Med. Chir. (Tokyo) 46(9), 421-428 (2006).
69. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 68(2), 126-131 (2007). (Pubitemid 47087900)
70. Ikenoya M, Hidaka H, Hosoya T et al. Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem. 81(1), 9-16 (2002). (Pubitemid 34808850)
71. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93(2-3), 225-232 (2002). (Pubitemid 34615563)
72. Zhang Z, Ottens AK, Larner SF et al. Direct Rho-associated kinase inhibition induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell. Mol. Biol. Lett. 11(1), 12-29 (2006). (Pubitemid 44504042)
73. Tatsumi S, Mabuchi T, Katano T et al. Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 131(2), 491-498 (2005). (Pubitemid 40222456)
74. Ray P, Wright J, Adam J et al. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorg. Med. Chem. Lett. 21(4), 1084-1088 (2011).
75. Fang X, Yin Y, Chen YT et al. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J. Med. Chem. 53(15), 5727-5737 (2010).
76. Doe C, Bentley R, Behm DJ et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 320(1), 89-98 (2007). (Pubitemid 46025723)
77. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 50(1), 17-24 (2007). (Pubitemid 47220442)
78. Schueller O, Tong W, Ferkany JW, Sweetnam P. Abstract 1216: selective ROCK 2 inhibition attenuates arterial plaque formation in an ApoE knockout mouse model. Circulation 114,(II) 228 (2006).
79. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics. from pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 67(2), 171-177 (2010).
80. Boerma M, Fu Q, Wang J et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis 19(7), 709-718 (2008).
81. Feng Y, Cameron MD, Frackowiak B et al. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Bioorg. Med. Chem. Lett. 17(8), 2355-2360 (2007). (Pubitemid 46484293)
82. Ross-MacDonald P, De Silva H, Guo Q et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol. Cancer Ther. 7(11), 3490-3498 (2008).
83. Scott RW, Hooper S, Crighton D et al. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J. Cell Biol. 191(1), 169-185 (2010).
84. Harrison BA, Whitlock NA, Voronkov MV et al. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J. Med. Chem. 52(21), 6515-6518 (2009).
85. Sleebs BE, Levit A, Street IP et al. Identification of 3-aminothieno[2,3-b] pyridine-2-carboxamides and 4-aminobenzothieno[3,2-d] pyrimidines as LIMK1 inhibitors. Med. Chem. Commun. 2, 977-981 (2011).
86. Sleebs BE, Ganame D, Levit A et al. Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors. Med. Chem. Commun. 2, 982-986 (2011).
87. Tanaka J, Ito M, Feng J et al. Interaction of myosin phosphatase target subunit 1 with the catalytic subunit of type 1 protein phosphatase. Biochemistry 37(47), 16697-16703 (1998). (Pubitemid 28543930)
88. Tan I, Seow KT, Lim L, Leung T. Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related Cdc42-binding kinase {alpha}. Mol. Cell. Biol. 21(8), 2767-2778 (2001). (Pubitemid 32244921)
89. Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 7(3), 255-261 (2005). (Pubitemid 40331126)
90. Totsukawa G, Yamakita Y, Yamashiro S et al. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 150(4), 797-806 (2000). (Pubitemid 30663416)
91. Gaggioli C, Hooper S, Hidalgo-Carcedo C et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9(12), 1392-1400 (2007). (Pubitemid 350201752)
92. Hidalgo-Carcedo C, Hooper S, Chaudhry SI et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat. Cell Biol. 13(1), 49-58 (2011).
93. Tan I, Lai J, Yong J, Li SF, Leung T. Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase. FEBS Lett. 585(9), 1260-1268 (2011).
94. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 172, 993-999 (1990).
95. Lee SK, Qing WG, Mar W et al. Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase C. J. Biol. Chem. 273(31), 19829-19833 (1998). (Pubitemid 28367046)
96. Chan SL, Lee MC, Tan KO et al. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 278(23), 20453-20456 (2003). (Pubitemid 36806340)
97. Murray BW, Guo C, Piraino J et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl Acad. Sci. USA 107(20), 9446-9451 (2010).
98. Cammarano MS, Nekrasova T, Noel B, Minden A. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol. Cell. Biol. 25(21), 9532-9542 (2005). (Pubitemid 41507853)
99. Parrini MC, Lei M, Harrison SC, Mayer BJ. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell 9(1), 73-83 (2002). (Pubitemid 34127772)
100. Lei M, Lu W, Meng W et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102(3), 387-397 (2000).
101. Chong C, Tan L, Lim L, Manser E. The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity. J. Biol. Chem. 276(20), 17347-17353 (2001).
102. Deacon SW, Beeser A, Fukui JA et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 15(4), 322-331 (2008). (Pubitemid 351508427)
103. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell Biol. 10(11), 1356-1364 (2008).
104. Bouquier N, Fromont S, Zeeh JC et al. Aptamer-derived peptides as potent inhibitors of the oncogenic RhoGEF TGAT. Chem. Biol. 16, 391-400 (2009).